All articles by prameela vegi
prameela vegi
British In Vitro Diagnostics Association welcomes first strategy for Medical Technology from the Government
The Department of Health and Social Care published the first strategy for medical technology today. The British In Vitro Diagnostics Association (BIVDA) welcomes this as another step forward to achieving the wider use of essential diagnostic tests and enabling technology which can really support better healthcare for patients and save resource for the NHS.
Certest Biotec: More than Diagnostics
The campaign More than Diagnostics that Certest will run throughout 2023 is a declaration of intent with respect to the transformation that the company has gone through, accelerated by the COVID-19 pandemic.
Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
This new test for researchers specifically targets the XBB.1.5 Omicron sub-variant and runs on the real-time PCR platforms LightCycler® 480 II* and cobas® z480.
Results from the test will help closely track the virus’ lineage and provide insights into the epidemiology and impact it has on public health.
Concern from the World Health Organisation centres around the XBB.1.5 high transmissibility and growth advantage.1
Pioneering research from UAE students driving the future of the region’s healthcare industry
• Arab Health to support the next generation of healthcare specialists in the region with the launch of the Future Doctor Programme for undergraduates and postgraduates
• Groundbreaking medical research by students from the UAE outlining healthcare issues in the region to be recognised during the event
• Arab Health returns to the Dubai World Trade Centre from 30 January – 2 February
Zentiva extends its collaboration with Adalvo and strengthens its offering in Respiratory, CNS and Dermatology
PRAGUE, Jan. 9, 2023 /PRNewswire/ — Zentiva is pleased to announce that we have extended our strategic partnership with Adalvo, signing a licensing deal for three molecules, within Europe.
FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of Alzheimer’s disease
STOCKHOLM, Jan. 9, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that under the Accelerated Approval pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb[1] (Brand Name in the U.S.: LEQEMBI™) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (“protofibrils[2]”) and insoluble forms of amyloid beta (Aβ) for the treatment of Alzheimer’s disease (AD). The accelerated approval is based on Phase 2b data in early AD patients which demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of AD. Using the recently published data from the large global confirmatory Phase 3 clinical trial, Clarity AD, Eisai will work quickly to file a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway. The approval of lecanemab-irmb by the FDA entitles BioArctic to a milestone payment of MEUR 25 from Eisai.
ProtonDx and Katalyst announce strategic partnership to distribute Dragonfly™ in vitro diagnostic
London, UK – 09 January 2023: ProtonDx, an in vitro diagnostic company designing, manufacturing and marketing rapid, accurate, multi‑pathogen, point‑of‑need diagnostic solutions, announced a strategic partnership with innovative commercial POCT provider Katalyst Laboratories, to distribute ProtonDx’s DragonflyTM rapid in vitro diagnostic system.